Transcutaneous electrical acupoint stimulation for postoperative urinary retention after radical hysterectomy for cervical cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, blinded, single-center, randomized controlled trial enrolling 76 patients with postoperative urinary retention after radical hysterectomy for cervical cancer, randomized 1:1 to TEAS plus usual care or sham TEAS plus usual care. The primary outcome is change in post-void residual (PVR) volume, and secondary outcomes include successful catheter removal rate after intervention, urinary tract infection assessment, and patient quality of life. Treatments are delivered according to a standardized TEAS protocol and compared with a sham device to maintain blinding. Eligible participants are adults aged 18–70 with an indwelling catheter for more than 14 days but less than one year and without prior urinary disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* (1) Age range of 18-70 years, expected survival period ≥ 6 months; (2) Meets diagnostic criteria, with an indwelling catheter duration of more than 14 days but less than 1 year; (3) No history of urinary system diseases before surgery; (4) Clear consciousness, unobstructed communication, daily living ability, patients or family members can learn TEAS operation; (5) No serious systemic diseases such as heart, liver, brain, kidney, etc; (6) Karnofsky functional status score (KPS) ≥ 70 points; (7) Voluntarily participate and sign a written informed consent form.

Exclusion Criteria:

* (1) Obstructive urinary retention, such as urethral stricture or stones; (2) combined with other serious systemic diseases, advanced cachexia; (3) Patients with pacemaker implantation or metal implantation in the body; (4) The treatment site has skin lesions or is not suitable for TEAS treatment in other populations; (5) Physical or mental disorders with cognitive impairment; (6) Other clinical trial participants who are currently involved in affecting the results of this study; (7) Those who do not agree to participate in clinical trials; (8) The evaluator has determined that the participant is not suitable to participate in this study.

Where it's running

• Zhejiang Cancer Hospital
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Chao Lu
• Email: luchao@zjcc.org.cn
• Phone: 15869128904

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Electroacupuncture for Postoperative Urinary Retention After Cervical Cancer Surgery

  This trial tests whether electroacupuncture can help people with POUR after radical hysterectomy for cervical cancer, compared with a sham treatment.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07253194

• Impact of Tamsulosin on Urinary Retention After Urogynecology Surgery

  This study tests if giving tamsulosin before pelvic surgery can help patients avoid needing a catheter after their operation.

  Recruiting Phase 3 TriHealth Inc. · Cincinnati, Ohio · NCT06843538

• Me capegfilgrastim to help prevent neutropenia in advanced breast cancer patients on chemotherapy

  This real-world registry tests whether mecapegfilgrastim used with chemotherapy helps prevent low white blood cells in adults with advanced breast cancer.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07899099

• Pucotenlimab and Anlotinib with Chemo Before Surgery for Early-Stage Triple-Negative Breast Cancer

  This study tests a combo of pucotenlimab, anlotinib, and nab-paclitaxel before surgery in adults with newly diagnosed, stage II-III triple-negative breast cancer that is PD-L1 known.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou · NCT07896668

• Anti-PD-1 with chemotherapy and intraperitoneal nab-paclitaxel for untreated advanced gastric cancer with ascites

  This study tests whether adding anti-PD-1 therapy to standard chemotherapy plus intraperitoneal nab-paclitaxel can help patients with untreated advanced gastric cancer and malignant ascites.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07855640

• Carbon ion lattice radiotherapy for large thoracic tumors

  This study tests a carbon ion lattice radiotherapy approach, after induction chemoimmunotherapy, in adults with unresectable locally advanced NSCLC or other thoracic solid tumors.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07744074

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.